Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
33 results about "High affinity receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The high-affinity IgE receptor, also known as FcεRI, or Fc epsilon RI, is the high-affinity receptor for the Fc region of immunoglobulin E (IgE), an antibody isotype involved in the allergy disorder and parasites immunity. FcεRI is a tetrameric receptor complex that binds Fc portion of the ε heavy chain of IgE.
Melanocortin 1 receptor selective compounds
A compound of general formula (1) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are H or methyl, R13, R14, R15 and R16 are H or alkyl, wherein L1 and L2 are linkers selected from single bond, methyl, ethyl, wherein R19, R20 and R21 are H or —CH2X, NT is selected from H, hydroxyl, alkyl, aminoacid, aminoacid analogue, polypeptide and functional group, CT is selected from hydrogen, hydroxyl, alkyl, aminoacid, aminoacid analogue, polypeptide and functional group shows high selectivity and high affinity for MC1-receptors in combination with effective stimulation or inhibiton of cAMP formation in MC1-receptor expressing cells but low affinity for other subtypes of MC-receptors and may be used to treat a wide range of inflammatory conditions. Also disclosed is a DNA molecule and a corresponding vector encoding the compound, a fusion protein comprising a copy of it, a vector comprising DNA encoding the fusion protein, and a pharmaceutical composition comprising the compound.
Owner:ACTION PHARM AS
Thiazolopyridine
The present invention relates to compounds of formula I wherein R1 and R2 are described hereinbelow. These compounds have high affinity to A2A receptors and good selectivity to A1 and A3 receptors. These compounds are useful, inter alia, in the treatment of Alzheimer's disease, depression, Parkinson's disease and ADHD.
Owner:F HOFFMANN LA ROCHE & CO AG
Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody
InactiveUS20060165704A1Limit and prevent down-regulationPrevent diseaseAntibacterial agentsBiocideDisease monitoringVirulent characteristics
The present invention relates to methods for the control of virulence of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. Derivatives of cell signalling molecules are conjugated to suitable carrier proteins and used to isolate high affinity receptors recognising the native signal molecule(s). By binding to signalling molecules, the receptors reduce and maintain extra-cellular concentrations of signal molecules below the threshold level that would otherwise result in certain opportunistic pathogens adopting a virulent form, and can transform virulent organisms to non-virulent states. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease monitoring and management, and in related applications where the host for infection is an animal or plant.
Owner:HAPTOGEN
Chimeric chemokines receptors capable of making T cells tend to tumor locations
ActiveCN103965362AEfficient arrivalOvercome the problem of not being able to effectively reach the tumor sitePeptide/protein ingredientsGenetic material ingredientsHigh concentrationImmunologic function
The invention belongs to the fields of molecular biology and immunology, and relates to chimeric chemokines receptors capable of making T cells tend to tumor locations. Specifically, the chimeric chemokines receptors are formed in a manner that a peptide fragment of a generated factor secreted by efficiently-combined tumor cells or tumor stromal cells is connected with a transmembrane region originated from a high-affinity receptor and a signal domain peptide fragment capable of making the T cells efficiently migrated through hinge structures. A membrane outer peptide fragment receives a corresponding factor signal and transfers the signal into cells, and a related path for promoting T cell chemotaxis is started through an intracellular region of the signal domain peptide fragment capable of promoting the migration of the T cells, so that the T cells modified by the chimeric chemokines receptors have a characteristic of migrating to the corresponding factor high concentration direction, and a normal tumor killing activity is not weaken, so as to ensure the tumor adoptive cell therapy effector T cells can efficiently reach the tumor nidus locations, and play a role in treatment.
Owner:SHANGHAI CELL THERAPY GRP CO LTD
Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody
InactiveUS7812134B2Reduce bacterial infectionImprove life expectancyAntibacterial agentsImmunoglobulins against bacteriaDisease monitoringBacteroides
Owner:HAPTOGEN
High affinity receptors for helicobacter pylori and use thereof
InactiveUS20060122148A1Inhibit bindingAntibacterial agentsCosmetic preparationsHelicobacter pyloriOligosaccharide
The present invention describes an oligosaccharide substance or receptor binding to Helicobacter pylori, and the use thereof in, e.g., pharmaceutical and nutritional compositions for the treatment of conditions due to the presence of Helicobacter pylori. The invention is also directed to the use of the receptor for diagnostics of Helicobacter pylori.
Owner:GLYKOS FINLAND
Elisa screening method for inhibitors of human IgE binding to the high affinity receptor, FcepsiRIalpha
The present invention is directed to an Assay for high capacity screening of substances interfering with the attachment of human IgE to its high affinity receptor and / or of substances capable of detaching already bound IgE from this receptor and for the differential analysis between autoimmune disorders and classical allergies.
Owner:NOVARTIS AG
Interleukin 2 mutant
PendingCN113667004ARetain biological activityRemove affinityPeptide/protein ingredientsAntibody mimetics/scaffoldsDimerNatural Killer Cell Inhibitory Receptors
The invention provides an interleukin 2 mutant, a fusion protein, an antibody or a conjugate containing the mutant, and a pharmaceutical composition containing the mutant, the fusion protein, the antibody or the conjugate. Compared with wild-type interleukin 2, the mutant eliminates binding with IL-2R[alpha], reduces binding with an IL-2R[beta][gamma] dimer, but keeps stimulating proliferation of tumor immune cells, including but not limited to proliferation of T cells and NK cells. According to the IL-2 mutant, the affinity to a high-affinity IL-2 receptor is eliminated, and meanwhile, the affinity to a medium-affinity IL-2 receptor is reduced. The interleukin 2 mutant provided by the invention is more suitable for the conjugate of the fusion protein and the antibody. The interleukin 2 mutant provided by the invention has extremely few mutation sites relative to wild type interleukin 2, so that the potential immunogenicity is extremely low. Meanwhile, various side effects caused by immunotherapy by using natural IL-2 are avoided.
Owner:SHANGHAI GP BIOTECH CO LTD
Anti-human FcepsilonRIalpha subunit monoclonal antibody and application thereof
InactiveCN104212770APromote growthStrong divisionMicroorganism based processesImmunoglobulins against cell receptors/antigens/surface-determinantsAllergic dermatitisDisease
The invention discloses an anti-human FcepsilonRIalpha subunit monoclonal antibody and application thereof. A hybridoma cell strain producing the monoclonal antibody is collected in China Center for Type Culture Collection, and the collection number thereof is CCTCC NO:201211. The anti-human FcepsilonRIalpha subunit monoclonal antibody prepared by the invention can be combined with a human IgE high-affinity receptor FcepsilonRIalpha, and can be used for detecting FcepsilonRIalpha expression on the surface of a cell; and the monoclonal antibody is of great significance for prevention and treatment of mast cell and basophilic granulocyte related diseases such as allergic dermatitis, dermatomyositis, psoriasis and the like, and has great clinical application value. The hybridoma cell strain provided by the invention is favorable in cell strain growth vigor, uniform in cell body size, muddy or transparent and vigorous in division, and has a proliferative potential of infinite division.
Owner:李莉 +1
Il-2 orthologs and methods of use
ActiveUS20210196796A1Reduce the binding forcePeptide/protein ingredientsGenetically modified cellsIntracellular signallingCell biology
The present disclosure relates to hIL2 orthogonal ligands (“IL2 orthologs”) that specifically and selectively bind to the extracellular domain (ECD) a transmembrane polypeptide comprising of a modified hCD122 polypeptide. The binding of the hIL2 ortholog to the modified hCD122 polypeptide participates in the transduction pathway of intracellular signaling resulting in a biological activity of the native intracellular signaling patterns associated with hIL2 binding to either the intermediate or high affinity hIL2 receptor but which exhibits selectivity to an engineered cell expressing an hCD122 orthogonal receptor. The hIL2 orthologs of the present invention exhibit significantly reduced binding relative to their binding to the extracellular domain of wild type hCD122, either alone or when hCD122 is present in the form of an endogenous high or intermediate affinity hIL2 receptors.
Owner:SYNTHEKINE INC
Human interleukin-2 variant or derivative thereof
The invention relates to a human interleukin-2 variant or a derivative thereof, in particular to IL-2 with one or more mutant amino acids or a derivative of the IL-2 with one or more mutant amino acids. The human interleukin-2 variant or the derivative thereof has eliminated or reduced affinity with a high-affinity receptor (IL-2Ralpha / beta / gamma), and the affinity with a medium-affinity receptor(IL-2Rbeta / gamma) is kept. According to the human interleukin-2 variant or the derivative thereof, a good basis is provided for protein patent medicines.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +2
Method for delivering a cytokine using a colloidal metal
InactiveUS8137989B2Eliminate side effectsLess or non-toxicBiocidePeptide/protein ingredientsColloidCytokine
In accordance with the present invention, a composition and method is provided that allows for the administration of a biologically-active factors to a human or animal. The present invention can be used to treat a disease with a biologically-active factor or combination of biologically-active factors, or can be used to safely vaccinate a human or animal against a biologically-active factor. It can also be used as a method for the delivery of biologically-active factors for the treatment of disease. Additionally, the present invention also includes a method of targeted drug delivery for the treatment of disease through the administration of custom complexes containing of one or more biologically active factors bound to a colloidal metal where at least one of the biologically-active factors is capable of binding a high affinity receptor on a cell surface.
Owner:CYTIMMUNE SCI
Regulation of receptor expression through delivery of artificial transcription factors
InactiveCN103998609APolypeptide with localisation/targeting motifSenses disorderPromoterHigh affinity receptor
The invention relates to an artificial transcription factor comprising a polydactyl zinc finger protein targeting specifically a receptor gene promoter fused to an inhibitory or activatory protein domain, a nuclear localization sequence, and a protein transduction domain. In particular examples these receptor gene promoters regulate the expression of the endothelin receptor A, the endothelin receptor B, the Toll-like receptor 4 or the high-affinity IgE receptor. Artificial transcription factors directed to the endothelin A or B receptors are useful in the treatment of diseases modulated by endothelin, such as cardiovascular diseases, and, in particular, eye diseases, e.g. retinal vein occlusion, retinal artery occlusion, macular edema, optic neuropathy, central serous chorioretinopathy, retinitis pigmentosa, Leber's hereditary optic neuropathy, and the like. Artificial transcription factors directed to the Toll-like receptor 4 or the IgE receptor are useful for the treatment of autoimmune disorders, and the like, and allergic disorders, respectively.
Owner:ALIOPHTHA
Compositions and methods for treatment of her2 positive metastatic breast cancer
InactiveCN109475576AOrganic active ingredientsMammal material medical ingredientsAntigenAntiendomysial antibodies
Contemplated immunotherapies include co-administration of an activated NK cell that is further genetically modified and a cancer therapeutic agent. In preferred embodiments, activated NK cells are further modified to taNK cells, which include a chimeric antigen receptor (CAR) with affinity for a cancer specific antigen, a cancer associated antigen, or a tumor specific antigen. Activated NK cells can also be further genetically modified to include high affinity Fc receptor CD16a (V158). Appropriate cancer therapeutic agents include chemotherapeutic drugs (e.g., nant-paclitaxel) or cancer targeted antibodies (e.g., trastuzumab).
Owner:NANTCELL INC +1
Regulation of expression of high-affinity immunoglobulin e (ige) receptor beta-chain
The present invention provides a polynucleotide comprising all or a part of the nucleotide sequence identified as SEQ ID NO:1 that regulates transcription of the human high-affinity IgE receptor (FcεRl) β-chain gene, and a method for regulating transcription of the FcεRl β-chain gene which comprises the step of promoting binding between a transcription regulatory complex containing MZF-1 and the transcription regulatory region of the FcεRl β-chain gene that contains the nucleotide sequence identified as SEQ ID NO: 1. In addition, the present invention provides a screening method and a kit therefor that utilizes the method for regulating transcription of the FcεRl β-chain gene having the step of promoting binding between a transcription regulatory complex containing MZF-1 and the transcription regulatory region of the FcεRl β-chain gene that contains the nucleotide sequence identified as SEQ ID NO:1, thereby enabling development of a novel agent for the prevention and treatment of allergic diseases.
Owner:NIHON UNIVERSITY
Treatment of allergic diseases with chimeric protein
ActiveUS20180230236A1Reduce free serum IgE levelDecreasing IgE levelSenses disorderAntibody mimetics/scaffoldsLinker peptideDisease cause
The present invention provides a chimeric protein comprising: a) a single chain variable fragment (scFv) that binds to a mammalian IgE at an epitope within the amino acid sequence VDGQKATNIFPYTAPGTK (SEQ ID NO:1) of canine IgE or at an epitope within the corresponding amino acid sequence of a different mammalian species; b) a linker peptide; and c) an amino acid sequence comprising an IgE high affinity receptor alpha chain, and methods of use thereof.
Owner:NORTH CAROLINA STATE UNIV
Method for expressing human IgE high affinity receptor protein in vitro
InactiveCN104212860AReduce manufacturing costReduce the difficulty of productionCell receptors/surface-antigens/surface-determinantsPeptide preparation methodsEscherichia coliIon exchange
The invention discloses a method for expressing human IgE high-affinity receptor protein in vitro. The method is used for expressing the human IgE high-affinity receptor protein by virtue of escherichia coli fusion; next, the expressed human IgE high-affinity receptor protein is purified by use of a method comprising protease digestion, affinity chromatography, gel chromatography and ion-exchange column chromatography so that the pure IgE high-affinity receptor protein can be obtained. Large-scale soluble expression of the human IgE high-affinity receptor protein in vitro can be realized by use of the method, and therefore, the production cost and the production difficulty of the IgE high-affinity receptor protein are greatly reduced.
Owner:SHENZHEN PKU HKUST MEDICAL CENT
Haplotypes of the FCER1A gene
InactiveUS20050196829A1Improve efficiencyImprove reliabilityMutant preparationImmunoglobulins against cell receptors/antigens/surface-determinantsMedicineGenotyping
Owner:GENAISSANCE PHARMA INC
Mutant protein for proliferating immune cells
PendingCN111944036AReduce or eliminate affinityAffinity preservationPeptide/protein ingredientsAntibody mimetics/scaffoldsMutated proteinReceptor
The invention provides IL-2 mutant protein, fusion protein or a conjugate comprising the IL-2 mutant protein, and a pharmaceutical composition comprising the IL-2 mutant protein, and the fusion protein or conjugate. Compared with the wild type IL-2 protein, the glycosylation pattern of the IL-2 mutant protein in the invention is altered, so that the affinity of the mutant IL-2 protein to a high-affinity IL-2 receptor is eliminated or reduced, and the affinity of the mutant IL-2 protein to a medium-affinity IL-2 receptor is substantially retained. The IL-2 mutant protein in the invention has extremely low immunogenicity, so that the IL-2 mutant protein can be used for immunotherapy, but does not have various side effects generated by immunotherapy by utilizing natural IL-2.
Owner:SHANGHAI GP BIOTECH CO LTD
A kind of chimeric molecular converter of T cell signal and its use
ActiveCN103965361BImprove proliferative abilityEnhance secretory functionPeptide/protein ingredientsGenetic material ingredientsSide effectSignalling molecules
Owner:SHANGHAI CELL THERAPY GRP CO LTD
Substituted ureas and methods of treating mental illness using the same
ActiveUS10301277B2Low toxicityLess securityOrganic active ingredientsNervous disorderSubstituted ureaNeuropsychiatric disease
A cyclohexane derivative as shown by formula IB or a stereoisomer or a salt thereof, has a high affinity for D3 receptors and 5-hydroxytryptamine, has a lower affinity for D2 receptors, shows a high selectivity for D3 / D2 receptors, and can be used as a therapeutic drug against neuropsychiatric diseases.wherein; X is N or CH; R isR is optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I and C1-C6 alkyl; and the C1-C6 alkyl is optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, and I.
Owner:ZHEJIANG JINGXIN PHARMA +2
Anti-human Fc epsilon RI alpha subunit monoclonal antibody and application thereof
InactiveCN104293738AUniform sizeHigh value of basic researchMicroorganism based processesImmunoglobulins against cell receptors/antigens/surface-determinantsAllergic dermatitisDisease
The invention discloses an anti-human Fc epsilon RI alpha subunit monoclonal antibody and application thereof. A hybridoma cell strain capable of producing the monoclonal antibody is preserved in China Center for Type Culture Collection and has the preservation number of CCTCC NO. C201326. The anti-human Fc epsilon RI alpha monoclonal antibody prepared by the invention can be bound with high-affinity receptor Fc epsilon RI alpha of human IgE and can be applied in detecting the expression of cell surface Fc epsilon RI alpha. The monoclonal antibody has important significance and relatively large clinical value for prevention and treatment of mast cell and basophilic granulocyte-related diseases, such as allergic dermatitis, dermatomyositis and psoriasis. The hybridoma cell strain disclosed by the invention grows well, and is bright and transparent, the cell body is uniform, the division is strong and the hybridoma cell strain has indefinitely divided proliferative capability.
Owner:李莉 +1
Treatment of allergic diseases with chimeric protein
ActiveUS11352443B2Reduce free serum IgE levelLower Level RequirementsSenses disorderAntibody mimetics/scaffoldsDiseaseEpitope
The present invention provides a chimeric protein comprising: a) a single chain variable fragment (scFv) that binds to a mammalian IgE at an epitope within the amino acid sequence VDGQKATNIFPYTAPGTK (SEQ ID NO:1) of canine IgE or at an epitope within the corresponding amino acid sequence of a different mammalian species; b) a linker peptide; and c) an amino acid sequence comprising an IgE high affinity receptor alpha chain, and methods of use thereof.
Owner:NORTH CAROLINA STATE UNIV
Glial cell line-derived neurotrophic factor receptor
InactiveUS20030175876A1Organic active ingredientsNervous disorderNervous systemTransmembrane signaling
The present invention relates to glial cell line-derived neurotrophic factor (GDNF), a potent neurotrophin that exhibits a broad spectrum of biological activities on a variety of cell types from both the central and peripheral nervous systems. The present invention involves the cloning and characterization of a high affinity receptor for GDNF. This molecule has been named GDNF receptor (GDNFR) since it is the first known component of a receptor system. Nucleic acid and amino acid sequences are described for GDNFR protein products. A hydrophobic domain with the features of a signal peptide is found at the amino terminus, while a second hydrophobic domain at the carboxy terminus is involved in the linkage of the receptor to the cell membrane. The lack of a transmembrane domain and cytoplasmic region indicates that GDNFR requires one or more accessory molecules in order to mediate transmembrane signaling. GDNFR mRNA is widely distributed in both nervous system and non-neural tissues, consistent with the similar distribution found for GDNF.
Owner:AMGEN INC
Fc FUSION HIGH AFFINITY IgE RECEPTOR a-CHAIN
ActiveUS20180044402A1Improve stabilityExcellent neutralizing activity against IgECell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsReceptorAmino acid
Provided is an Fc fusion high affinity IgE receptor α-chain having excellent stability at low pH.An Fc fusion protein comprising:(i) a high affinity IgE receptor α-chain; and(ii) an Fc region of IgG1, whereina linker fragment region between the (i) and the (ii) is the amino acid sequence shown in SEQ ID NO: 2.
Owner:SENJU PHARMA CO LTD
Anti-idiotypic antibodies against antibodies which inhibit the binding of immunoglobuline to its high affinity receptor
InactiveCN1268644CImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsDiseaseAntibody fragments
Antibodies and antibody fragments which are anti-idiotypic to an antibody that interferes with the binding of the C epsilon 3 region of IgE to its high affinity receptor (mimobodies), particularly, which are anti-idiotypic to BSW17 (BSW17-mimobodies) are described, as well as their use as pharmaceuticals, especially vaccines, in the treatment of IgE-mediated diseases.
Owner:NOVARTIS AG
Fc FUSION HIGH AFFINITY IgE RECEPTOR ALPHA-CHAIN
InactiveUS20180312566A1Improve stabilityExcellent neutralizing activity against IgECell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsReceptorAmino acid
Owner:KISSEI PHARMA
Establishment method of high-throughput drug screening model based on icam-1 signaling pathway
The invention belongs to the technical field of drug molecular model building, and in particular relates to a method for building a high-throughput drug screening model based on the ICAM-1 signaling pathway. ICAM‑1 is an important immune system component and an important characterization molecule in many diseases. The present invention focuses on the ICAM-1 molecule and its regulatory network, uses engineered yeast as a medium to construct a novel drug screening system, displays the ICAM-1 high-affinity receptor LFA-1 insertion domain on the surface of the yeast and expresses green in its cells fluorescent protein. If the drug acts on ICAM-1 and its signaling pathway, it will affect the number of yeast cells and unit animal cells. Drugs can be quickly screened through the difference in fluorescence intensity. The fluorescence intensity of yeast can be used to achieve efficient, simple, and efficient detection of ICAM-1 expression. Economical high-throughput drug screening. The present invention has high plasticity, and respective drug screening platforms can be established according to animal cells of different disease types.
Owner:HUAZHONG AGRI UNIV
Preparation method and application of dermatophagoides pteronyssinus allergen specific IgG Fab antibody fragment
ActiveCN113683693ALow immunogenicityReduce the binding forceSerum immunoglobulinsImmunoglobulins against animals/humansAntibody fragmentsReceptor
The invention relates to the technical field of biology, and particularly discloses a preparation method and application of a dermatophagoides pteronyssinus allergen specific IgG Fab antibody fragment. The method comprises the following steps: 1) collecting and diluting serum, and filtering to obtain a serum sample; loading the sample on a protein A affinity chromatography column, and then eluting a serum IgG antibody to obtain a serum total IgG antibody; 2) adding dermatophagoides pteronyssinus to a affinity chromatographic column for coupling, adding the serum total IgG antibody in the step 1), and eluting the dermatophagoides pteronyssinus specific IgG antibody; and 3) adding agarose-linked papain into the house dust mite specific IgG antibody, uniformly mixing, incubating, centrifuging, and taking supernatant, thereby obtaining the house dust mite specific immunoglobulin G. The dermatophagoides pteronyssinus allergen specific IgG Fab antibody fragment can compete with IgE to bind to dermatophagoides pteronyssinus and reduce the formation of a dermatophagoides pteronyssinus-IgE compound, so that the binding of the dermatophagoides pteronyssinus-IgE compound to effector cells expressing IgE low-affinity receptors and IgE high-affinity receptors is reduced, the activation of sensitized cells is reduced, and the occurrence of inflammatory response is controlled.
Owner:阳江市人民医院
In vivo models for rabGEF1-dependent signaling and functions
InactiveUS20060037089A1Enhanced functional responseImprove responseNew breed animal cellsMaterial analysisAntigenDisease
Non-human transgenic animal models and cells derived therefrom are provided for RabGEF1 function. RabGEF1 is a negative regulator of FcεRI-dependent mast cell activation and T cell activation via the T cell receptor and a lack of RabGEF1 results in the development of skin inflammation in vivo. The mast cells derived from such animals exhibit enhanced Ras-mediated signaling and functional responses when activated through high affinity IgE receptors. These cells show significant potentiation of IgE and antigen-dependent secretion of 3 classes of mast cell mediators, providing a useful source of mast cells for screening assays. The animals and cells derived therefrom are also useful for screening biologically active agents that may modulate RabGEF1 function, including therapeutic agents for the treatment of skin disorders, such as eczema, psoriasis, and the like, or for the treatment of other mast cell-associated disorders, including allergic disorders, such as asthma and hay fever, and certain autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. Inhibiting RabGEF1 function may be useful in those conditions in which it is desirable to enhance T cell and / or mast cell function, such as in AIDS or other immune deficiency disorders.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com